Can Earning Season Save Growth Stocks? | Sam Burns
Forward Guidance
00:00
Pfizer's Earning Story Is Getting Better
The analysts have dramatically raised their estimates for Pfizer over the last few months both in terms of how many analysts have raised and how much they've raised so those are the two main components of merit. The fundamentals are clearly getting better in terms of the underlying earning story for Pfizer now the black line has gone up that means that the stock has responded it's it's outperforming the market. In the bottom section there is the evaluation the relative valuation of Pfizer versus the us large cap s and b 500 universeso you can see that the purple line there has been going down which means the stock is beginning cheaper relative to the market.
Transcript
Play full episode
